Targeted therapies in CLL: mechanisms of resistance and strategies for management
about
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemiaThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaIdelalisib in the management of lymphoma.Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsNovelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.The landscape of new drugs in lymphomaProfile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Reviving the guardian of the genome: Small molecule activators of p53.Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor.Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition.TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL LymphocytesSilencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia
P2860
Q26751006-42AA8200-CE11-4DF1-A186-0D8AFCC0BCFAQ28075504-85A51C73-04B5-448F-BAFA-DF8B1EEE31C9Q34529311-67AE94BA-ED16-4CAD-B510-B7B46FF6035DQ36028930-E0AA289A-6DC9-4359-BC62-5BDD9C6B4286Q37209768-695DD441-99C1-47BB-8B2C-36B6E8C152F3Q38594364-4818E77A-6103-4992-A959-363786384C55Q38818283-A2B29463-0BF9-4493-92F4-2ABC20150EDCQ38872460-80038F4F-9788-4879-98EF-B01C34FEF507Q38881164-363C1118-4A3A-4FA8-AA01-A259B264A548Q38968891-D8F1E027-4C07-474E-9CB1-B41BF1435531Q39034465-F8A34EDA-55B3-428C-A9C5-8FE849F8EB86Q39061630-68B0F8A1-2919-42E3-B4AD-86B08A8423B7Q39145934-BB8D41A1-5F9F-4993-9C83-40B19069CB46Q39169789-7BA7D209-8B3E-4E11-92CE-DB27B16E0162Q39205536-B1F0DEEA-8B09-498A-A8AE-4F366DC47973Q39414732-89469CD2-4518-4882-9F81-7B4FE5958361Q42370806-EB4D84FE-73A3-45F9-A839-6ED6635A7608Q42399878-0DDE93AA-2DA0-461C-A8C4-C3958753EEDFQ43146957-EEB8F20E-275D-4E87-87C8-CEABD56D2AD4Q47300115-BA53B732-2275-49A1-95AD-FD8504130D15Q47840209-B41D3359-6067-4D0F-B1E2-63EFDE8E945DQ47882529-CBA0C36A-E9F1-4526-93C7-0E39CB920700Q49226138-78703ADB-BFFF-46A1-96C5-F9B8074F0E09Q49546562-78504F8E-FA3F-4BB9-AE28-7723BD178868Q49724479-83CD1970-96B3-4C54-A98B-9B9A56B9ECC0Q51716282-7DEC44AE-93A8-4024-89E6-E1D72C707115Q53963822-372870A6-E7D1-4881-9C35-67B88F3360B0Q57491548-DB414916-BB01-4530-9F96-E0EBBFC8F839Q59137904-5F074CF8-1FD9-4E29-BCAC-460987FBCE9A
P2860
Targeted therapies in CLL: mechanisms of resistance and strategies for management
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@ast
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@en
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@nl
type
label
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@ast
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@en
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@nl
prefLabel
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@ast
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@en
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@nl
P2860
P3181
P1433
P1476
Targeted therapies in CLL: mechanisms of resistance and strategies for management
@en
P2093
A. J. Johnson
J. A. Woyach
P2860
P3181
P356
10.1182/BLOOD-2015-03-585075
P407
P577
2015-07-23T00:00:00Z